

2007

Madrid. Spain. 14-15th March



CENTRO ONCOLÓGICO  
MD ANDERSON  
INTERNATIONAL ESPAÑA

THE UNIVERSITY OF TEXAS  
MD ANDERSON  
CANCER CENTER

secretaría técnica:



Avda. Arroyo del Santo, 28 - 28042 Madrid  
contacto: Emilia Sánchez. Móvil: 626 484 286. E-mail: emilia.sanchez@totalteam.es



joint MDACC-CNIO-MDAIE Lymphoma meeting

# Advances in targeted therapy in Lymphoproliferative disorders



CENTRO ONCOLÓGICO  
MD ANDERSON  
INTERNATIONAL ESPAÑA

THE UNIVERSITY OF TEXAS  
MD ANDERSON  
CANCER CENTER

**OBJECTIVE**

The meeting aims to actively discuss the latest advances in the management of lymphoma patients, bringing together leading scientists and clinicians in the closely related fields of lymphoma molecular pathogenesis and tumor progression, diagnosis, treatment and new therapeutic targets.

**ORGANIZATION**

Larry Kwak (MDACC)  
Felipe Samaniego (MDACC)  
Miguel A. Piris (CNIO)  
Juan F. García (MDAIE)  
José F. Tomás (MDAIE)

**SECRETARY****VENUE**

Centro Nacional de Investigaciones Oncológicas.  
Melchor Fernández Almagro, 3 - 28029 Madrid, Spain

**SESSION I****SESSION II****Wednesday, 14th. Afternoon.**

16:00-16:15

**Welcome:** Mariano Barbacid (CNIO), Ramón Colomer (MDAIE)

**Multiple Myeloma**

*Chairman: J.F. San Miguel*

16:15-16:45

*Jesús F. San Miguel M.D., Ph.D. (Hematology, Hospital Clínico Universitario, Salamanca).* **Update on the use of new drugs in the management of Multiple Myeloma.**

16:45-17:15

*Qing Yi, M.D. (MDACC, Houston).* **Immunomodulators for therapy of Multiple Myeloma.**

17:15-17:45

*Sergio Giral, M.D., Ph.D. (MDACC, Houston).* **Transplantation in Multiple Myeloma.**

17:45-18:15

*Larry Kwak, M.D., Ph.D. (MDACC, Houston).* **Vaccine therapy for Lymphoma and Multiple Myeloma.**

18:15-18:30

**Discussion and remarks.**

18:30-19:00

*Coffee break*

**Chronic Lymphocytic Leukemia**

*Chairman: F. Bosch*

19:00-19:30

*Estella Matutes, M.D., Ph.D. (Haemato-Oncology, Royal Marsden Hospital, London).* **News on CLL diagnosis.**

19:30-20:00

*Francesc Bosch, M.D., Ph.D. (Hematology, Hospital Clinic, Barcelona).* **Perspectives on the use of new therapeutic and prognostic factors for Chronic Lymphocytic Leukaemia.**

20:30-20:45

**Discussion and remarks.**

*Dinner*

**SESSION III****SESSION IV****SESSION V****Thursday, 15th****B-Cell Lymphoma. Biology**

*Chairman: M.A. Piris*

09:00-09:30

*Miguel A. Piris (CNIO, Madrid).* **Lymphoma molecular machinery: a bridge between the diagnosis and the therapy.**  
*Felipe Samaniego, M.D. (MDACC, Houston).* **Apoptosis regulation in Lymphoma.**

09:30-10:00

10:00-10:30

*Almudena R. Ramiro, Ph.D. (CNIO, Madrid).* **Role of genomic instability, p53 and AID in Lymphoma IgH translocations.**

10:30-11:00

*Manuel Esteller, M.D., Ph.D. (CNIO, Madrid).* **Epigenetics and Lymphoma: Basic Knowledge and Translational Uses.**

11:00-11:30

*Coffee break*

**B-Cell Lymphoma. Therapy**

*Chairman: J.F. Tomás*

11:30-12:00

*José F. Tomás (Hematology, MDAIE, Madrid).* **Front-line treatment in Follicular Lymphoma.**

12:00-12:30

*Sattva Neelapu, M.D. (MDACC, Houston).* **Immunotherapy for B-Cell Indolent Lymphoma.**

12:30-13:00

*Luis Fayad, M.D. (MDACC, Houston).* **Chemotherapy intense treatment of Large B-Cell Lymphoma.**

13:30-13:30

**Discussion and remarks.**

13:30-15:00

*Lunch*

15:00-15:30

*Anas Younes, M.D. (MDACC, Houston).* **Novel chemotherapy agents for Lymphoma.**

15:30-16:00

*Tim Illidge. (Manchester University).* **Radioimmunotherapy: a new strategy in the treatment of NHL.**

16:00-16:30

*Barbara Pro, M.D. (MDACC, Houston).* **Therapy of T-Cell Lymphoma.**

16:30-17:00

**Discussion and remarks.**

17:00-17:30

*Coffee break*

**Hodgkin Lymphoma**

*Chairman: J.F. García*

17:30-18:00

*Carlos Montalbán (Internal Medicine, Hospital Ramón y Cajal, Madrid).* **Hodgkin Lymphoma diagnosis and treatment: new data and opportunities.**

18:00-18:30

*Juan F. García (Pathology, MDAIE, Madrid).* **Hodgkin Lymphoma, diagnosis and prognostic new findings.**

18:30-18:45

**Discussion and remarks.**

18:45-19:00

*José F. Tomás (MDAIE).* **Conclusion remarks.**